On April 9, 2026 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, reported that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP, Selective EP300, and Selective ARID1B degrader programs will be featured as poster presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"FHD-909 is advancing in the clinic in collaboration with Lilly as the first potential selective SMARCA2 inhibitor for the treatment of SMARCA4-mutant cancers. We are excited to present new, compelling preclinical data further supporting potential expansion opportunities in combination with an anti-PD-1 antibody, as part of Dr. Bellon’s oral presentation at this year’s AACR (Free AACR Whitepaper)," said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. "Poster presentations will also highlight additional preclinical data characterizing our wholly owned Selective CBP, Selective EP300, and Selective ARID1B degrader programs. Collectively, these data underscore the differentiated profiles of our pipeline programs which may translate to improved therapeutic outcomes for difficult to treat cancers with significant unmet need."

Oral Presentation Details

Title: Targeting chromatin regulatory proteins in hematologic malignancies
Town Meeting: Chemistry, Hematologic Malignancies – From Molecules to Medicine – Driving Breakthroughs in Blood Cancer Treatment: A CICR-HMWG Town Hall
Session Date/Time: Monday, April 20, 6:30 p.m. – 8:30 p.m. PDT
Presenter: Gromek Smolen, VP, Biology, Foghorn Therapeutics

Title: Leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)
Session: Molecular/Cellular Biology and Genetics, Chemistry, Drug Development – Synthetic Lethality in Oncology: Progress Made, Pitfalls Encountered, and the Path Forward
Session Date/Time: Tuesday, April 21, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics

Title: Towards new cancer medicines with degraders of chromatin regulatory proteins
Session: Chemistry, Drug Development, Experimental and Molecular Therapeutics – Induced Proximity Pharmacology: Degraders and Beyond
Session Date/Time: Wednesday, April 22, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Danette Daniels, VP, Degrader Platform, Foghorn Therapeutics

Poster Presentation Details

Title: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies
Session: Experimental and Molecular Therapeutics – Quantitative Pharmacology and Translational Modeling
Poster Number: 1828 / 16
Session Date/Time: Monday, April 20, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Meiyun Lin, Senior Scientist, Pharmacology, Foghorn Therapeutics
Abstract: Click here

Title: Leveraging selective degradation of CBP and EP300 for potent anti-cancer activity
Session: Chemistry – Targeted Protein Degradation and Induced Proximity
Poster Number: 5163 / 13
Session Date/Time: Tuesday, April 21, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Karolina Mizeracka, Principal Scientist, Cell Biology, Foghorn Therapeutics
Abstract: Click here

Title: Identification of first-in-class selective ARID1B degraders
Session: Experimental and Molecular Therapeutics – Proximity-Induced Drug Discovery 2
Poster Number: 5792 / 19
Session Date/Time: Tuesday, April 21, 2:00 p.m. – 5:00 p.m. PDT
Presenter: Madeleine Henley, Senior Scientist, Foghorn Therapeutics
Abstract: Click here

Title: Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors
Session: Experimental and Molecular Therapeutics – Epigenetic Modulators 2
Poster Number: 7075 / 22
Session Date/Time: Wednesday, April 22 9:00 a.m. – 12:00 p.m. PDT
Presenter: Darshan Sappal, Director, Biology, Foghorn Therapeutics
Abstract: Click here

Dr. Bellon’s presentation and the posters will be accessible under the Science section of the Company’s website.

(Press release, Foghorn Therapeutics, APR 9, 2026, View Source [SID1234664291])

On April 9, 2026 Boehringer Ingelheim and Click Therapeutics reported a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.3 Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing authorization rights, to Click Therapeutics. To support this transition, Boehringer has made a $50M Series D strategic investment and provided dedicated commercial funding to help bring CT-155 to patients, if cleared by the FDA. CT-155 was co-developed by Boehringer and Click.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Boehringer Ingelheim’s selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building," said David Benshoof Klein, CEO and founder of Click Therapeutics. "We are eager to take the lead with CT-155 and are focused on getting this FDA-designated Breakthrough Device to patients after clearance by the FDA."

At the core of Click’s commercialization strategy will be the clinical data from the Phase III CONVOKE study (CONVOKE; NCT05838625).2,3 The randomized, double-blind, controlled study investigated the effectiveness and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia experiencing negative symptoms.3,4

The study met its primary endpoint, as presented at the 38th Annual European College of Neuropsychopharmacology (ECNP) Congress2, which was change in experiential negative symptoms from baseline to 16 weeks as measured by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP).2,3 Treatment with CT-155 demonstrated a Cohen’s D effect size of -0.36 (p value= 0.0003) reflective of a 6.8-point improvement of negative symptoms severity as measured by CAINS-MAP at 16 weeks (vs. 4.2-point in digital control arm), representing a 62% relative improvement.2

CT-155 was well-tolerated and demonstrated an adverse event (AE) profile consistent with past studies. The AE rates with CT-155 and the digital control arm were 8.3% vs 13.4%, respectively.2 There were no trial discontinuations attributed to CT-155 and two (2) for the digital control arm. There were no serious AEs related to either group.2

Additional clinical and engagement data is being generated in real-world-like settings through the ENSPIRUS study (NCT06791122).5 Boehringer Ingelheim will continue to lead completion of the ENSPIRUS study.

"Fostering science to create new treatments for patients is at the heart of what we do," said Jan Stefan Scheld, Head of Global Therapeutic Areas at Boehringer Ingelheim. "The collaboration with Click Therapeutics has played a vital role in advancing a potentially meaningful innovation for people living with schizophrenia and we believe this agreement enables Click to continue on our successful co-development of CT-155, leveraging their capabilities and expertise to maximize its impact."

About CT-155

CT-155 (BI 3972080) is an investigational prescription digital therapeutic that aims to provide interactive psychosocial intervention techniques as an adjunct to standard antipsychotic therapy to people living with schizophrenia experiencing negative symptoms.1,3,6 CT-155 was co-developed by Click Therapeutics, Inc. and Boehringer Ingelheim.3

In 2024, CT-155 was granted Breakthrough Device designation by regulatory authorities in the U.S.1

CT-155 has not been authorized by any regulatory authorities. Safety and effectiveness have not been established by any regulatory authority.

About the CONVOKE study

CONVOKE (NCT05838625) was a Phase III, multicenter, randomized, double-blind, 16-week study evaluating the efficacy and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia and experiential negative symptoms.3 The study enrolled adults and late adolescents with schizophrenia who were stable on antipsychotic medication.3

The primary endpoint evaluated improvement in experiential negative symptoms as an adjunct to standard of care as measured by changes from baseline to week 16 in the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure Scale (CAINS-MAP).3

Other endpoints include: change from baseline in CAINS-MAP at week 8; change from baseline in CAINS expressivity scale (CAINS-EXP) at weeks 8 and 16; change from baseline in positive symptoms measured by the Positive and Negative Syndrome Scale (PANSS) at weeks 8 and 16; change from baseline in social functioning measured by the Personal and Social Performance Scale (PSP) at weeks 8 and 16; and patient global impression of improvement measured by Patient Global Impression of Improvement Scale (PGI-I) at weeks 8 and 16.

(Press release, Boehringer Ingelheim, APR 9, 2026, View Source [SID1234664290])

On April 9, 2026 Oxford BioTherapeutics ("OBT"), is a clinical stage oncology company focused on the discovery and development of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies enabled by its OGAP-Verify platform reported a multi-year, selective target collaboration with Bristol Myers Squibb (NYSE: BMY, "BMS") focussed on the discovery and development of novel T-cell engager therapies for solid tumours.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OBT will leverage its proprietary OGAP-Verify target discovery and validation platform, to identify novel, tumour-selective targets for solid cancers and generate next-generation T-cell engager molecules. The collaboration extends beyond discovery, with OBT assuming responsibility for the design and delivery of development candidates, highlighting the company’s expanding evolution into a fully integrated discovery and preclinical development platform. Subsequent research, development and commercialisation activities for these targets will be led by BMS.

Under the terms of the agreement, OBT will receive an upfront inclusive of research funding and the potential for significant downstream milestone payments and royalties on commercialised products from BMS. Financial terms were not disclosed.

The collaboration with BMS marks OBT’s third partnership with a major pharmaceutical company in the past 12 months, following strategic partnerships with GSK and Roche in 2025.

"Collaborating with Bristol Myers Squibb, a global leader in oncology, represents an important milestone for OBT and underscores the momentum behind our partnerships with leading pharmaceutical companies," said Christian Rohlff, PhD, Chief Executive Officer of OBT. "This new partnership builds on the proven strength of our platform to identify and validate highly differentiated, tumour-selective targets and reflects the growing confidence in our ability to translate that science into development-ready therapeutic candidates. By combining OGAP-Verify’s discovery and validation capabilities with Bristol Myers Squibb’s expertise in translating oncology innovation into clinical and commercial outcomes, we are confident that together we can advance a new generation of innovative cancer therapies that have the potential to make a meaningful difference for patients."

OBT’s OGAP-Verify discovery platform enables highly sensitive identification of oncology targets with improved attributes for drug development, supporting the creation of differentiated antibody-based therapies.

(Press release, Oxford BioTherapeutics, APR 9, 2026, View Source [SID1234664289])

On April 9, 2026 Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) reported that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has successfully completed the safety run-in stage of a Phase II clinical trial in the first-line treatment of advanced biliary tract cancer (BTC). Based on favorable safety and encouraging preliminary efficacy data, the study has progressed into the expansion phase, with the first patient already enrolled.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study is led by Dr. Jian Zhou from Zhongshan Hospital, Fudan University, and is being conducted across multiple clinical sites in China. A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well tolerated, with a favorable safety profile and no new safety signals observed. Preliminary efficacy assessments indicated encouraging tumor reduction trends. Based on these results, the study has advanced to the expansion phase with accelerated enrollment underway.

Opamtistomig is a uniquely engineered bispecific antibody designed to simultaneously block PD-1/L1-mediated immune suppression and selectively activate the 4-1BB co-stimulatory pathway. By restoring T-cell functionality and expanding effector T-cell populations within the tumor microenvironment, Opamtistomig has the potential to deliver more potent and durable anti-tumor activity than PD-1/PD-L1 blockade alone, particularly in difficult-to-treat and immunotherapy-resistant tumors. To date, Opamtistomig has demonstrated first- or best-in-class potential in Phase II or registrational clinical trials across three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and extrapulmonary neuroendocrine carcinoma (EP-NEC).

Executive Commentary
Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, commented: "Based on favorable safety and encouraging efficacy signals from the safety run-in cohort, Opamtistomig has advanced into the expansion phase of the Phase II BTC study, with strong support from investigators unanimously. This represents an important milestone for the program and reinforces our confidence in its clinical potential. As additional efficacy data mature, we plan to initiate a confirmatory study, leveraging our extensive clinical network to accelerate development and bring a differentiated immunotherapy option to patients with advanced biliary tract cancer as early as possible."

About Biliary Tract Cancer
Biliary tract malignancies primarily include gallbladder cancer and intrahepatic/extrahepatic cholangiocarcinoma, with approximately 419,100 new cases globally in 2024. These malignancies are predominantly ‌adenocarcinomas‌ with high invasiveness, and most cases are diagnosed at advanced stages, leading to ‌poor prognosis‌ (5-year survival rate <5%)‌. Currently, global incidence of biliary tract malignancies is rising, with the highest prevalence observed in Asian countries.

Although ‌PD-1/L1 inhibitors combined with chemotherapy‌ have been approved as first-line treatment for advanced biliary tract malignancies, clinical benefits remain limited: ‌Modest improvement in median overall survival (OS)‌ (from ~11.5 to 12.8 months)‌ and ‌Low objective response rate (ORR)‌ (<30%)‌. These gaps highlight ‌unmet medical needs‌ for more effective therapies‌.

About Opamtistomig (LBL-024)
Opamtistomig (LBL-024) is a potential first-in-class bispecific antibody that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. It is the first 4-1BB–targeting bispecific antibody globally to advance to a single-arm pivotal trial as monotherapy, and it holds promise to become the first approved therapy specifically for extrapulmonary neuroendocrine carcinoma (EP-NEC)—a rare malignancy with substantial unmet clinical need.

Developed using Leads Biolabs’ proprietary X-Body bispecific platform, Opamtistomig features a 2:2 molecular format, incorporating two binding domains each for PD-L1 and 4-1BB with an optimized affinity ratio. This unique design enables dual functionality: reversing PD-L1–mediated immune suppression while selectively enhancing T-cell activation, resulting in a potent and synergistic anti-tumor immune response.

In two ongoing clinical studies in China, Opamtistomig has demonstrated promising efficacy and a favorable safety profile in patients with advanced EP-NEC, both as monotherapy and in combination with chemotherapy. Given the absence of a globally accepted standard of care for EP-NEC, these results support the advancement of a single-arm pivotal study toward potential accelerated approval.

Recognizing its clinical potential, Opamtistomig received Breakthrough Therapy Designation (BTD) from China’s National Medical Products Administration (NMPA) in October 2024, and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of neuroendocrine carcinoma in November 2024. Additionally, in January 2026, Opamtistomig was granted Fast Track Designation (FTD) by the FDA and ODD by the European Commission for the treatment of EP-NEC, further underscoring its potential to address unmet medical needs in this patient population.

Mechanistically, 4-1BB agonism can reactivate exhausted T cells and promote robust T-cell proliferation, offering significant promise for PD-1/PD-L1–resistant or immunologically "cold" tumors. Beyond EP-NEC, Opamtistomig has received clinical trial approvals across multiple tumor types with high unmet medical needs, including small cell lung cancer (SCLC), biliary tract cancer (BTC), ovarian cancer (OC), non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC), and malignant melanoma. Encouraging clinical activity has already been observed in NSCLC, SCLC, BTC, OC, and other indications, underscoring Opamtistomig’s potential as a broad-spectrum immuno-oncology therapy.

(Press release, Nanjing Leads Biolabs, APR 9, 2026, View Source [SID1234664288])

On April 9, 2026 Kainova Therapeutics ("the Company"), a key player for breakthrough treatments in immuno-oncology and inflammation, reported dosing of the first patient in the European expansion of its DOMISOL Phase I/II clinical trial evaluating DT‑7012, a proprietary Treg‑depleting anti‑CCR8 monoclonal antibody, in patients with advanced solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This dosing follows the initiation of the DOMISOL Phase I/II study in Australia, announced in October 2025, marking a significant milestone in the global clinical development of DT-7012, Kainova Therapeutics’ lead immuno-oncology program. The European expansion (NCT06819735) includes leading oncology centers in France, led by renowned early-phase clinical investigators, including Dr Lauriane Eberst at Hôpitaux Universitaires de Strasbourg, Professor Antoine Italiano at Institut Gustave Roussy in Paris, and Dr Maxime Brunet at Institut Bergonié Bordeaux.

Professor Antoine Italiano, MD PhD, Head of Precision Medicine at Institut Gustave Roussy and member of Kainova Therapeutics’ Scientific Advisory Board, said: "This study brings together strong clinical expertise and advanced translational capabilities, creating an important opportunity to explore how targeted Treg depletion may translate into meaningful benefit for patients with advanced solid tumors. DT‑7012 offers a novel, differentiated approach to precisely address CCR8 biology and reshape the tumor microenvironment."

Dr Jean‑Marie Cuillerot, Chief Medical Officer of Kainova Therapeutics, commented: "Dosing of the first patient in Europe marks an important step in the clinical maturation of our flagship program, DT‑7012. The DOMISOL study has been designed to generate a comprehensive clinical and biological profile for DT‑7012 across both monotherapy and combination settings, including paired biopsies to directly assess the intra tumoral Treg depletion. These data will be essential to inform dose selection and support the next phases of development."

The Phase I/II multicenter, open‑label DOMISOL clinical study is evaluating DT‑7012 as monotherapy in a Phase I dose-escalation, in combination with the immune checkpoint inhibitor pembrolizumab in a Phase Ib dose-escalation in patients with advanced solid tumors, and in selected tumor types in a Phase II component focused on clinical efficacy. The primary objectives include determining the maximum tolerated dose (MTD) or maximum administered dose (MAD) of DT‑7012 as monotherapy and assessing the safety and tolerability of DT‑7012 in combination with pembrolizumab.

The study also includes a translational research program with paired tumor biopsies to evaluate intratumoral Treg depletion induced by DT‑7012, providing a direct demonstration of DT-7012’s mechanism of action to turn the immunosuppressive tumor microenvironment into an immunocompetent one.

Sean A. MacDonald, Chief Executive Officer of Kainova Therapeutics, added: "As our flagship program, DT‑7012 is central to Kainova Therapeutics’ strategy and reflects our commitment to advancing breakthrough GPCR‑modulating therapies in immuno‑oncology and inflammation. With multiple high‑value milestones ahead, 2026 is a pivotal year for Kainova Therapeutics. We are excited to expand the DOMISOL trial into Europe and we look forward to sharing compelling data in the coming quarters."

(Press release, Kainova Therapeutics, APR 9, 2026, View Source [SID1234664287])